利妥昔单抗治疗原发干燥综合征外周神经系统受累有效
发表者：刘蕊
日期：2015-03-05
浏览次数：219
评论次数：0
摘要 目的：评价利妥昔单抗(RTX)治疗原发干燥综合征(pSS)周围神经系统(PNS)受累的疗效
方法：分析在法国AIR注册的有周围神经系统受累的干燥综合征患者数据
结果：共入选17例患者（平均年龄60岁（44~78岁），女性14例）。其中11例患者（65%）在患病3个月时出现周围神经病变。Rankin 评分记录在第3，6，9个月时分别由3 (1-5)降到 2 (1-5), 2 (1-5) 和2 (1-6) (p=0.02)。欧洲干燥综合征疾病活动指数在3，6，9个月后分别由18 (10-44) 降到 11 (5-20), 11 (5-29) 和 12 (5-30) (p<0.05)。RTX在治疗3个月时对10例有血管炎或冷凝球蛋白血症的患者(1组)中的9例（90%）均有疗效，而对没有血管炎或冷凝球蛋白血症的7例患者中的2例（26%）有效(p=0.03)。1组患者无论Rankin 评分还是欧洲干燥综合征疾病活动指数均有显著下降。
结论：RTX对有血管炎或冷凝球蛋白血症的pSS患者的PNS治疗有效。
附原文：Abstract OBJECTIVE:To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement.METHODS:Patients with pSS and PNS involvement who were included in the French AIR registry were analysed.RESULTS:17 patients (age 60 years (44-78 years); 14 were female) were analysed. Neurological improvement was noted in 11 patients (65%) at 3 months. Rankin scale decreased from 3 (1-5) to 2 (1-5), 2 (1-5) and 2 (1-6) after 3, 6 and 9 months (p=0.02). European Sjögren's Syndrome Disease Activity Index decreased from 18 (10-44) to 11 (5-20), 11 (5-29) and 12 (5-30) after 3, 6 and 9 months (p<0.05). RTX was effective in neurological involvement in 9/10 patients with vasculitis or cryoglobulinaemia (90%) (group 1) at 3 months and in 2/7 cases (29%) without cryoglobulinaemia and vasculitis (p=0.03). Rankin and European Sjögren's Syndrome Disease Activity Index scales decreased significantly in group 1. CONCLUSION:RTX seems effective in cryoglobulinaemia or vasculitis-related PNS involvement in pSS.
引自：Mekinian A, Ravaud P, Hatron PY,et al.Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervoussystem involvement: results from the AIR registry. Ann Rheum Dis. 2012 Jan;71(1):84-7. （注：干燥综合症病人或亲属可加QQ群交流，群号： 118194945 ，本网站站长私人微信号： ssgzz88 ）
方法：分析在法国AIR注册的有周围神经系统受累的干燥综合征患者数据
结果：共入选17例患者（平均年龄60岁（44~78岁），女性14例）。其中11例患者（65%）在患病3个月时出现周围神经病变。Rankin 评分记录在第3，6，9个月时分别由3 (1-5)降到 2 (1-5), 2 (1-5) 和2 (1-6) (p=0.02)。欧洲干燥综合征疾病活动指数在3，6，9个月后分别由18 (10-44) 降到 11 (5-20), 11 (5-29) 和 12 (5-30) (p<0.05)。RTX在治疗3个月时对10例有血管炎或冷凝球蛋白血症的患者(1组)中的9例（90%）均有疗效，而对没有血管炎或冷凝球蛋白血症的7例患者中的2例（26%）有效(p=0.03)。1组患者无论Rankin 评分还是欧洲干燥综合征疾病活动指数均有显著下降。
结论：RTX对有血管炎或冷凝球蛋白血症的pSS患者的PNS治疗有效。
附原文：Abstract OBJECTIVE:To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement.METHODS:Patients with pSS and PNS involvement who were included in the French AIR registry were analysed.RESULTS:17 patients (age 60 years (44-78 years); 14 were female) were analysed. Neurological improvement was noted in 11 patients (65%) at 3 months. Rankin scale decreased from 3 (1-5) to 2 (1-5), 2 (1-5) and 2 (1-6) after 3, 6 and 9 months (p=0.02). European Sjögren's Syndrome Disease Activity Index decreased from 18 (10-44) to 11 (5-20), 11 (5-29) and 12 (5-30) after 3, 6 and 9 months (p<0.05). RTX was effective in neurological involvement in 9/10 patients with vasculitis or cryoglobulinaemia (90%) (group 1) at 3 months and in 2/7 cases (29%) without cryoglobulinaemia and vasculitis (p=0.03). Rankin and European Sjögren's Syndrome Disease Activity Index scales decreased significantly in group 1. CONCLUSION:RTX seems effective in cryoglobulinaemia or vasculitis-related PNS involvement in pSS.
引自：Mekinian A, Ravaud P, Hatron PY,et al.Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervoussystem involvement: results from the AIR registry. Ann Rheum Dis. 2012 Jan;71(1):84-7. （注：干燥综合症病人或亲属可加QQ群交流，群号： 118194945 ，本网站站长私人微信号： ssgzz88 ）